Large gap with delayed quotes
|
Last quote
08/30/2025
-
02:00:00
|
Bid
08/29/2025 -
21:59:59
|
Bid Volume |
Ask
08/29/2025 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
1.13
-0.05
(
-4.24% )
|
1.13
|
49,300 |
1.14
|
8,300 |
Analysis date: 29.08.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 04.07.2025.
Interest
Very weak
Very weak
One star since 01.08.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 22.04.2025 at a price of 1.59.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 01.08.2025.
4wk Rel Perf
-20.69%
-20.69%
The four-week dividend-adjusted underperformance versus SP500 is 20.69%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 3.69%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 6.01%.
Mkt Cap in $bn
0.25
0.25
With a market capitalization <$2bn, ALLOGENE THERAPEUTICS is considered a small-cap stock.
G/PE Ratio
1.51
1.51
A "Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings" ratio higher than 1.5 indicates that the stock's price presents a discount to growth >40% in this case.
LT P/E
-1.10
-1.10
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
1.65%
1.65%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
12
12
Over the last seven weeks, an average of 12 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
128
128
For 1% of index variation, the stock varies on average by 1.28%.
Correlation
0.24
0.24
Stock movements are strongly independent of index variations.
Value at Risk
0.89
0.89
The value at risk is estimated at USD 0.89. The risk is therefore 78.56%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
29.03.2019
29.03.2019